GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2008

Pfizer Taps Aureon to Evaluate Prostate Cancer Patients’ Response to Hormone Therapy

  • Aureon Laboratories will establish quantitative biometrics to assess therapeutic responses in studies focusing on prostate cancer for Pfizer. The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome.

    The deal is an extension of a previous study performed by Aureon and Pfizer to evaluate prostatectomy samples from patients treated with neo-adjuvant androgen deprivation therapy (ADT).

    Aureon technology is also being used to develop Prostate Px+. This prognosticwill be used in men newly diagnosed with prostate cancer. The companies expect the product to be released this year.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?